Strategic partnerships SweetBio has ongoing and announced distribution partnerships with BioLab Sciences, Resolve Medical, Spartan Medical, and a collaboration with Veterans Affairs and Department of Defense channels. This indicates a strong path to market through distributors and federal contracts, presenting opportunities for co-marketing, site demonstrations, and expanded wound care product trials with hospital systems and government facilities.

Product expansion The launch of APIS, a bioengineered wound matrix, in early 2026 signals a broadened product portfolio and newer use cases beyond initial collagen plus honey products. Sales efforts can target hospitals and clinics seeking advanced wound care solutions for acute and chronic wounds, as well as integrate APIS into existing wound care programs.

Clinical adoption Past collaborations with Regional One Health and clinical publications suggest strong clinician interest and real-world application. Focus sales conversations on clinician champions, case studies, and education to accelerate adoption within hospital networks and innovation centers.

Publicity and credibility Media coverage of partnerships and funding, including Vamos Ventures backing and PR announcements, enhances credibility with procurement teams. Leverage these success stories in RFIs, vendor qualification packs, and at industry conferences to differentiate SweetBio from competitors.

Federal market access Existing engagement with Veterans Affairs and Department of Defense contracts through APIS distribution indicates capability to navigate federal procurement. Develop targeted outreach to military medical centers, federal supply schedules, and contract vehicles to expand government sales.